Nylidrin Hydrochloride

Nylidrin Hydrochloride (CAS No.: 849-55-8) is a synthetic small molecule adrenergic modulator, also known as buphenine hydrochloride, that is primarily categorized in pharmacology and translational biology workflows as a beta adrenergic receptor agonist with additional receptor level polypharmacology relevant to neuroimmune and antiviral discovery research. In mechanistic studies, it has been reported to engage beta adrenergic signaling associated with cyclic AMP dependent pathways and smooth muscle relaxation phenotypes, while separate electrophysiological and receptor functional assays indicate antagonistic activity at NR1A and NR2B containing NMDA receptor systems with potency in the submicromolar to low micromolar range, supporting its use in cross pathway target deconvolution and off target profiling. Experimental evidence from immune and inflammation models further shows suppression of IgG1 and IgE linked histamine release in sensitized guinea pig, rat, and human cell based systems, consistent with modulation of mast cell and basophil activation networks and downstream mediator output. Additional reports describe inhibitory effects on multiple influenza A H1N1 subtypes and reductions in selected inflammatory or injury associated biomarkers, making this compound suitable for exploratory screening in virology, immunopharmacology, and shock related pathophysiology models. In practical laboratory settings, Nylidrin Hydrochloride is commonly applied as a reference or comparator tool in cell assays, ex vivo tissue preparations, and animal studies designed to interrogate adrenergic, glutamatergic, and immune mediator pathways, and the concentrations or doses used in experiments typically depend on specific experimental designs and research objectives.